Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.

The Journal of molecular diagnostics : JMD - 1 Jun 2022

Wei Bo, Kang John, Kibukawa Miho, Arreaza Gladys, Maguire Maureen, Chen Lei, Qiu Ping, Lang Lixin, Aurora-Garg Deepti, Cristescu Razvan, Levitan Diane

Abstract excerpt

Pembrolizumab is approved for treating patients with unresectable or metastatic solid tumors with high tumor mutational burden (TMB), as assessed by the Food and Drug Administration-approved companion diagnostic FoundationOneCDx, after progression on prior treatment. To expand TMB assessment for enriching response to pembrolizumab, TMB measurement from TruSight Oncology 500 (TSO500) was evaluated in archival...

Topics

Join the communities discussing this publication.

Antibodies, Monoclonal, Humanized
Biomarkers, Tumor
High-Throughput Nucleotide Sequencing
Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35218944
DOI: 10.1016/j.jmoldx.2022.01.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.PMID 35218944Read ↗

Tumor Mutational Load: A Novel Predictor for Clinical Benefit of Pembrolizumab.Semantic proximity Read ↗

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.Semantic proximity Read ↗

Expert consensus on the detection and clinical application of tumor mutational burden.Semantic proximity Read ↗

Refining Tumor Mutational Burden as a Predictive Biomarker for Pembrolizumab: A Real-World Analysis in Japanese Patients.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker in Solid TumorsSemantic proximity Read ↗

Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy.Semantic proximity Read ↗

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.Semantic proximity Read ↗

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.Semantic proximity Read ↗

Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profilingSemantic proximity Read ↗

Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.Semantic proximity Read ↗

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.Semantic proximity Read ↗

Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and cliniciansSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.